Humanized Mouse and Rat Model Market by Type (Genetic, Cell-Based (CD34, PBMC, BLT)), Application (Neuroscience, Oncology, Toxicology, Immunology & Infectious diseases, Hematopoiesis), End Users, and Region - Global Forecast to 2027
Updated on : May 08, 2023
The global humanized mouse and rat model market in terms of revenue was estimated to be worth $237 million in 2022 and is poised to reach $338 million by 2027, growing at a CAGR of 7.4% from 2022 to 2027. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The major factors driving the growth of this market include increasing number of research activities involving humanized models, growing demand for personalized medicine, continuous support in the form of investments and grants from the government and private sector, rising usage of mice models in virology and infectious disease testing, and growth in the number of R&D activities carried out by pharmaceutical and biotechnology companies. However, the high cost of humanized mouse and rat models and regulations & laws regarding the ethical use of animals in medical research are expected to restrain the growth of this market during the forecast period.
Attractive Opportunities in Humanized Mouse and Rat Model Market
To know about the assumptions considered for the study, Request for Free Sample Report
Global Humanized Mouse and Rat Model Market Dynamics
DRIVER: Increasing research activities using humanized models
Continuous research is being undertaken for the development of treatments for immunodeficiency disorders, cancers, and other rare diseases. A majority of these research studies are highly dependent on animal models. Owing to this, market players are continuously focusing on bringing about innovations in mouse models. As highly advanced and innovative mouse models provide increased options to researchers, the demand for such models has increased in the market in recent years.
This technology is majorly used to produce animal models with more humanized pathological conditions, including genetic disorders. These models can also be used to determine drug effectiveness and the metabolism rate of drugs. Since disease models reflecting human physiology can be produced and used for more accurate non-clinical studies and drug discovery, the demand for humanized mouse and rat models is expected to be high among researchers.
RESTRAINT: Laws and regulations for the ethical use of animal models in research
Various regulations and laws have been laid down by the government for ensuring the ethical use of animals in research activities. Research institutes and companies carrying out studies on animals have to comply with these standards and requirements formulated for animal testing. In the US, the Animal welfare Act (AWA) and the Public Health Service Policy on Human Care and Use of Laboratory animals (PHS) are two main regulations governing the use of animals in research. The AWA is a federal law covering animals in research. It covers almost 90-95% of animals including rats, mice, and birds, which are bred for research. The US Department of Agriculture (USDA) enforces AWA, according to which businesses and individuals using regukated animals must be licensed or registered with USDA, and facilities with regulated animals must be inspected every year by the Animal and Plant Health Inspection Services (APHIS).
These guidelines ensure the smooth operation of animal studies and do not restrict research studies as long as they are abided by. However, complying with the mandatory regulations for the use of animal models is sometimes cumberson and time consuming and might hinder the use of animal models.
OPPORTUNITY: Rising demand for humanized PDX models
It is observed that xenografts develop well in immunodeficient models, and these immunodeficient models are majorly applied for creating PDX model. Although, these models do not deem fit for evaluating stroma-tumor interactions, and these are highly responsible for growth and progression of tumor in a patient. To overcome these issues Humanized PDX models are gaining popularity in the market.
Nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mouse models are now being reconstituted with bone marrow or peripheral blood cells, along with patient tumor implants, to generate humanized xenograft models. Such models prove to be a valuable platform to examine the contribution of xenogeneic immune cells to the overall anti-tumor immunity. These also help analyse immunotherapy drugs aimed at mobilizing the effector arm of the immune system.
As these models are gaining popularity in tumor biology in concert with associated stroma, efforts are underway to improve these models and apply them to various human cancer types. However, humanized PDX models are very costly compared to basic PDX models, owing to which their adoption is limited. JSR Corporation (Japan), Champions Oncology, Inc. (US), Charles River Laboratories (US), The Jackson Laboratory (US), and Oncodesign (France) are some of the major players focusing on the development of humanized PDX models.
CHALLENGE: Alternatives for animal testing
Alternative tests to humanized mouse model such as vitro methods and models based on human cells and tissue cultures; computerized patient-drug databases and virtual drug trials; computer models and simulations (in silico models); organs-on-chips; stem cell and genetic testing methods; and non-invasive imaging techniques, such as MRI, CT, and microdosing are reliable, cost-effective, practical, and expedient. It has been observed that the use of human tissue in toxicity testing is more accurate than using animal models. Rodents are predominantly used in toxicity and safety assessment studies. However, substantial efforts are being made to develop alternative testing methods that are accepted internationally. In the European Union, challenging timelines for phasing out several standard tests using laboratory animals were established in the seventh Amending Directive 2003/15/EC to Cosmetics Directive 76/768/EEC. In continuation of this policy, the new European Chemicals Legislation (REACH) favors methods that are alternative to conventional in vivo testing if validated.
Although some researchers are of the opinion that these alternatives are not very accurate and can in no way replace the use of animals, the 3Rs principle (replacement, reduction, and refinement) and ban on cosmetics testing on animals have led to the development and increased usage of these alternatives in various animal research establishments and institutes. This can pose a challenge for the market in the coming years.
Genomics: Market Ecosystem
The market ecosystem comprises of product providers and end users such as Pharmaceutical & Biotechnology companies, Academic & Research Institutes, and CROs. The suppliers for Humanized Mouse and Rat Model provide these research models for applications such as Preclinical Drug Development, Biomarker Analysis, Cancer research, among others. Overall, the market ecosystem for humanized mouse and rat models is a complex and dynamic network of different players, all working together to advance biomedical research and to develop new and better therapies for human diseases.
The prominent humanized mouse and rat model providers are Charles River Laboratories International, Inc. (US), The Jackson Laboratory (JAX) (US), Taconic Biosciences, Inc. (US), Crown Bioscience (US), Champions Oncology, Inc. (US), Hera BioLabs (US), genOway (France), Envigo (US), Vitalstar Biotechnology (China), inGenious Targeting Laboratory (US), AXENIS (France), TRANS GENIC (Japan), Harbour Antibodies (Netherlands), Oncodesign (France), Pharmatest Services (Finland), Ozgene Pty Ltd. (Australia), TransCure bioServices (France), Cyagen Biosciences (US), GVK BIO (India), and Biocytogen (US).
Ecosystem Analysis: Humanized Mouse and Rat Model Market
Source: Annual Reports, SEC Filings, Investor Presentations, Expert Interviews, and MarketsandMarkets Analysis
Based on type, humanized mouse model segment accounted for the largest market share of the humanized mouse and rat model market
Based on type, the market has been segmented into humanized mouse models and humanized rat models. The humanized mouse model segment accounted for the largest share of the Market. The plethora of immunodeficient strains available among mice is a major reason driving their use as humanized mouse models. Also, mice can undergo several genetic modifications compared to rats, which is an added advantage. Moreover, their ease of procurement, ease of manipulation, and the minimum facility requirement for keeping them under observation compared to rats is driving their use in the generation of humanized models.
Based on application, oncology segment accounted for the largest market share of the humanized mouse and rat model market
Based on application, the market is segmented into oncology, immunology and infectious diseases, neuroscience, hematopoiesis, toxicology, and other applications (allergies, rare diseases, graft-versus-host disease, and cardiovascular diseases). The oncology segment accounted for the largest share of the market in 2021. Growth in this segment can be attributed to the rising number of cancer research activities and increasing innovation to develop humanized mouse models tailored to meet the specific needs of cancer research.
Based on end users, pharmaceutical & biotechnology companies segment accounted for the largest market share of the humanized mouse and rat model market
Based on end user, the market has been segmented into pharmaceutical and biotechnology companies, contract research organizations (CROs), and academic and research institutions. The pharmaceutical and biotechnology companies segment accounted for the largest share of the market in 2021. Growth in this segment is majorly attributed to the increasing expenditure on R&D for drug development.
The North American market is projected to contribute the largest share for the humanized mouse and rat model market
The global market is segmented into five major regions—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. North America is the largest regional market for market in 2022, while Europe is the second-largest market. The major factors driving the growth of the North American market include the presence of a well-established pharmaceutical industry in the region, the high R&D expenditure, a strong presence of major service providers, and rising outsourcing of clinical testing by pharmaceutical and biotechnology companies in the region. Also, there is a rising focus on oncology research in the US, government support for the development of protein drugs, and growing stem cell research in Canada. These factors are boosting the demand for humanized mouse and rat models in North America.
To know about the assumptions considered for the study, download the pdf brochure
The humanized mouse and rat model market is dominated by a few globally established players such as Charles River Laboratories International, Inc. (US), The Jackson Laboratory (JAX) (US), Taconic Biosciences, Inc. (US), Crown Bioscience (US), Envigo (US), among others, are the key players that provided humanized mouse and rat model in the last few years. Major focus was given to the deals, expansions, and new product launches due to the changing requirements of end users across the world.
Humanized Mouse and Rat Model Market Report Scope
Market Revenue in 2022
Projected Revenue by 2027
Poised to Grow at a CAGR of 7.4%
Increasing research activities using humanized models
Rising demand for humanized PDX models
This report categorizes the humanized mouse and rat model market to forecast revenue and analyze trends in each of the following submarkets:
Humanized Mouse Model
- Genetic Humanized Mouse Models
- Cell-Based based Humanized Mouse Model
- CD34 Humanized Mouse Models (HU-CD34)
- PBMC Humanized Mouse Models
- BLT Humanized Mouse Models
- Humanized Rat Model
- Immunology and Infectious Diseases
- Other Applications
By End User
- Pharmaceutical & Biotechnology Companies
- Contract Research Organizations
- Academic & Research Institutes
- Rest of Europe (RoE)
Asia Pacific (APAC)
- South Korea
- Rest of Asia Pacific (RoAPAC)
- Latin America (LATAM)
- Middle East and Africa (MEA)
- In January 2022, Taconic Biosciences, Inc. (US) launched the huNOG-EXL EA (early access) humanized immune system (HIS) mouse.
- In October 2021, The Jackson Laboratory (US) acquired RMS Business of Charles River Laboratories Japan, Inc. (Japan) which is Charles River Laboratories Japan’s Research Models & Services (RMS) business as a wholly-owned subsidiary.
- In September 2021, Biocytogen (US) collaborated with Envigo (US) in order to support the research applications of the triple immunodeficient B-NDG mouse. Envigo is the exclusive provider of B-NDG mice in the US, Europe, and certain APAC regions.
- In March 2021, Charles River Laboratories International, Inc. (US) acquired Cognate BioServices, Inc. (US) a cell and gene therapy contract development and manufacturing organization (CDMO) offering comprehensive manufacturing solutions for cell therapies. The acquisition expanded Charles River's broad capabilities across the major CDMO platforms for cell and gene therapies.
Frequently Asked Questions (FAQ):
What is the projected market revenue value of the humanized mouse and rat model market?
The humanized mouse and rat model market boasts a total revenue value of $338 million by 2027.
What is the estimated growth rate (CAGR) of the humanized mouse and rat model market?
The global humanized mouse and rat model market has an estimated compound annual growth rate (CAGR) of 7.4% and a revenue size in the region of $237 million in 2022.
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global humanized mouse and rat model market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.
This research study involved the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, Companies’ House documents, investor presentations, and SEC filings of companies. The secondary sources referred to for this research study include publications from government sources, such as the American Association for Cancer Research, American Association for Laboratory Animal Science, European Society for Medical Oncology, European Association for Cancer Research, Federation for Laboratory Animal Science Associations, Alzheimer's Association, European Animal Research Association (EARA), Humanized Mouse Resource (HMR), National Center for Biotechnology Information (NCBI), and Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC). Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the market. It was also used to obtain important information about the key players, market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. Secondary data was collected and analyzed to arrive at the overall size of the global market, which was validated through primary research.
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing & sales directors, technology & innovation directors, and related key executives from various key companies and organizations operating in the humanized mouse and rat model market. The primary sources from the demand side included industry experts, purchase & sales managers, doctors, and personnel from research organizations. Primary research was conducted to validate the market segmentation, identify key players in the market, and as well as gather insights on key industry trends and key market dynamics.
The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Top-down and bottom-up approaches were used to estimate and validate the size of the global market and various other dependent submarkets. The following paragraph and figure shows an illustrative representation of the overall market size estimation process employed for this study.
Approach 1: Supply Side Analysis
- The global humanized mouse and rat model market size was obtained from annual reports, SEC filings, online publications, and extensive primary interviews. A percentage split was applied to arrive at the size of the market segments. Further splits were applied to arrive at the size of each subsegment. These percentage splits were validated by primary participants.
- The country-level market sizes obtained from annual reports, SEC filings, online publications, and extensive primary interviews were added up to reach the total market size for North America. By adding up the market sizes for all regions, the global market was derived.
After arriving at the market size, the total humanized mouse and rat model market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed, wherever applicable, in order to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.
A humanized mouse or rat model is an organism that has been genetically engineered to study immune responses to drugs or identify potential disease targets. Humanized mouse and rat models are widely used as research models to study human diseases and human genes. Researchers in academia and industry, as well as clinicians, use humanized mouse and rat models extensively in their research works. Humanized mouse and rat models are beneficial tools for immuno-oncology and infectious disease research. They have improved the ability to predict human responses to new therapeutics in clinical development.
- Research and consulting firms
- Biopharmaceutical manufacturers
- Pharmaceutical manufacturers
- Mouse model and service companies
- Government and private research institutes
- Manufacturers and suppliers of animal care products
- Clinical research organizations (CROs)
- Academic and research institutes
- Venture capitalists
- Animal care associations
- Public and private animal health agencies
- To define, describe, and forecast the humanized mouse and rat model market by type, application, end user, and region.
- To provide detailed information regarding the major factors influencing the growth of the market (drivers, restraints, opportunities, and challenges).
- To strategically analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall market.
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders.
- To forecast the size of market segments with respect to five main regions, namely, North America, Europe, the Asia Pacific (APAC), Latin America, and the Middle East & Africa.
- To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies.
- To track and analyze competitive developments such as acquisitions, collaborations, and product launches in the market.
- To benchmark players within the market using the proprietary "Competitive Leadership Mapping" framework, which analyzes market players on various parameters within the broad categories of business and product strategy.
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:
- Further breakdown of the RoE market, by country
- Further breakdown of the RoAPAC market, by country
- Further breakdown of the RoLA and MEA markets, by country
- Detailed analysis and profiling of additional market players (Up to five)
- Further breakdown of the application segment as per the product portfolio of prominent players operating in the market.
Growth opportunities and latent adjacency in Humanized Mouse and Rat Model Market